{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:42:03Z","timestamp":1788914523946,"version":"build-2803163510"},"reference-count":75,"publisher":"Informa UK Limited","issue":"20","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,10,31]]},"DOI":"10.2217\/fon.15.200","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T13:44:38Z","timestamp":1442238278000},"page":"2819-2830","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":33,"title":["A Comprehensive Review of Pacritinib in Myelofibrosis"],"prefix":"10.1080","volume":"11","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami S","family":"Komrokji","sequence":"additional","affiliation":[{"name":"Malignant Hematology Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,9,14]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-575373"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.277"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23384"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328955"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.10.025"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"e_1_3_3_11_1","volume-title":"54th American Society of Hematology Annual Meeting and Exposition.","author":"Mesa RA","year":"2012","unstructured":"Mesa RA , MehtaJ, WangHet al. Epidemiology of myeloproliferative disorders in US \u2013 a real world analysis. Presented at: 54th American Society of Hematology Annual Meeting and Exposition.Atlanta, GA, USA8\u201311December2012 (Abstract 2834)."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12256"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.1744.1744"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-014-0228-z"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500138200"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-1-5"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.25025"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S51253"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3264"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81166-6"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81167-8"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90066-7"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00054-6"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008271107"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20235"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1309"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2008.02.005"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397554"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0284"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3145"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1874.1874"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395228"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.1"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.69"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.57"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.3"},{"key":"e_1_3_3_46_1","first-page":"7","article-title":"FLT3 inhibitors: recent advances and problems for clinical application","volume":"77","author":"Kiyoi H","year":"2015","unstructured":"Kiyoi H . FLT3 inhibitors: recent advances and problems for clinical application. Nagoya J Med Sci77, 7\u201317 (2015).","journal-title":"Nagoya J Med Sci"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.178"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-436675"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1731"},{"key":"e_1_3_3_50_1","unstructured":"Kuriakose E\n. The role of the megakaryocyte in primary myelofibrosis. www.crt.org\/images\/files\/file\/The-Role-of-The-Megakaryocyte-in-Primary-Myelofibrosis.pdf"},{"key":"e_1_3_3_51_1","unstructured":"Jakafi \u00ae prescribing information. Incyte Corporation Wilmington DE USA (2014)."},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.916273"},{"key":"e_1_3_3_54_1","article-title":"Phase 2 study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis","volume":"29","author":"Deeg HJ","year":"2011","unstructured":"Deeg HJ , OdenikeO, ScottBLet al. Phase 2 study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. J. Clin. Oncol.29(Suppl.), Abstract 6515 (2011).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_55_1","volume-title":"53rd ASH Annual Meeting and Exposition.","author":"Verstovsek S","year":"2011","unstructured":"Verstovsek S , DeegHJ, OdenikeOet al. Phase 1\/2 study of SB1518, a novel jak2\/flt3 inhibitor, in the treatment of primary myelofibrosis. Presented at: 53rd ASH Annual Meeting and Exposition.San Diego, CA, USA, 10\u201313December2011 (Abstract 3082)."},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3905.3905"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484832"},{"key":"e_1_3_3_58_1","article-title":"Results of a Phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis","author":"Komrokji RS","year":"2011","unstructured":"Komrokji RS , WadleighM, SeymourJFet al. Results of a Phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Presented at: 53rd ASH Annual Meeting and Exposition.San Diego, CA, USA, 10\u201313 December 2011) (Abstract 282).","journal-title":"53rd ASH Annual Meeting and Exposition."},{"key":"e_1_3_3_59_1","volume-title":"2015 American Society of Clinical Oncology Annual Meeting.","author":"Mesa R","year":"2015","unstructured":"Mesa R , EgyedM, SzokeAet al. Results of the persist-1 Phase 3 study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocytopenia-myelofibrosis (pet-mf). Presented at: 2015 American Society of Clinical Oncology Annual Meeting.Abstract lba7006, Chicago, IL, USA, 29May\u20132June2015 (Abstract lba7006)."},{"key":"e_1_3_3_60_1","unstructured":"CTI BioPharma\n. Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326) NCT02055781. (2014). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02055781"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm200326p"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-012-9572-z"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.148"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.43"},{"key":"e_1_3_3_65_1","volume-title":"16th Congress of the European Hematology Association.","author":"Seymour J","year":"2011","unstructured":"Seymour J , ScottB, RobertsAet al. Long-term safety and efficacy analysis of the two Phase 1 studies of sb1518, a novel oral JAK2 inhibitor, in patients with advanced myeloid malignancies. Presented at: 16th Congress of the European Hematology Association.London, UK, 9\u201312June2011 (Abstract 0907)."},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4080.4080"},{"key":"e_1_3_3_67_1","volume-title":"18th Congress of the European Hematology Association.","author":"Al-Fayoumi S","year":"2013","unstructured":"Al-Fayoumi S , WangL, DeanJP, BennerS. Characterization of the pharmacokinetic and pharmacodynamic properties of pacritinib, a novel oral JAK2\/FLT3 inhibitor, in patients with myelofibrosis, AML, and lymphoma. Presented at: 18th Congress of the European Hematology Association.Stockholm, Sweden, 13\u201316June2013 (Abstract p983)."},{"key":"e_1_3_3_68_1","volume-title":"18th Congress of the European Hematology Association.","author":"Verstovsek S","year":"2013","unstructured":"Verstovsek S , CernohousP, KomrokjiRSet al. Safety overview of Phase 1\u20132 studies of pacritinib, a non-myelosuppressive JAK2\/FLT3 inhibitor, in patients with hematological malignancies. Presented at: 18th Congress of the European Hematology Association.Stockholm, Sweden, 13\u201316June2013 (Abstract p278)."},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.395.395"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.12.006"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.11.018"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13262"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.73"},{"key":"e_1_3_3_75_1","first-page":"588","article-title":"Phase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity","volume":"114","author":"Younes A","year":"2009","unstructured":"Younes A , FanaleM, McLaughlinPet al. Phase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity. ASH Annual Meeting Abstracts114, 588 (2009).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_76_1","first-page":"2830","article-title":"Phase 1 study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"116","author":"Younes A","year":"2010","unstructured":"Younes A , FanaleMA, McLaughlinP, CopelandA, ZhuJ, De Castro FariaS. Phase 1 study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. ASH Annual Meeting Abstracts116, 2830 (2010).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5223"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:34Z","timestamp":1719124954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,14]]},"references-count":75,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2015,10,31]]}},"alternative-id":["10.2217\/fon.15.200"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.200","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}